CPSA Portal will be unavailable from Dec. 13 – 15 due to a scheduled outage. Please complete your annual renewal and/or access documents and other applications outside of these dates. We apologize for the inconvenience..
Back to All News & Events

A reminder about prescribing high-potency narcotics for the treatment of opioid use disorder

Back to Messenger
June Messenger 2023, Prescribing, TPP Alberta | Posted June 8, 2023
Read time: 1 minute

In 2022, amendments to Alberta’s Mental Health Services Protection Regulation impacted the prescribing of high-potency opioid narcotics for the treatment of opioid use disorder (OUD). Conventional opioid agonist treatments such as methadone and slow-release oral morphine (SROM) were not impacted by the amendment.

High-potency opioid narcotics include any full agonist opioid drug, such as:

  • Hydromorphone
  • Diacetylmorphine (pharmaceutical heroin)
  • Fentanyl
  • Morphine
  • Oxycodone

High-potency opioid narcotics for OUD can only be prescribed through licensed AHS Opioid Dependency Programs for narcotic transition services. These medications must also be dispensed by AHS-contracted pharmacies. These requirements do not apply to high-potency opioids prescribed for treating chronic pain or other illnesses.

When prescribing a high-potency opioid narcotic to treat OUD, a corresponding indication must be provided on the TPP prescription form. For example:

  • Under Indication for therapy, checking Opioid Agonist Therapy (OAT/ODT)
  • Selecting Other (specify) and noting the following indications:
    • Opioid Abuse Disorder (OAD)
    • Opioid Addiction
    • Opioid Use Disorder (OUD)
    • Substance Use Disorder (SUD)

Resources:

If you have questions about prescribing to treat OUD, please email TPP.Info@cpsa.ab.ca.

Comments for this post are now closed. If you would like to share your feedback on this topic, please email support@cpsa.ca.